Received Jul 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
presented problems with her arm/ lifting her arm, locked to a certain point; Locked arm (tightness) after Shingrix first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injected limb mobility decreased in a female patient who received Herpes zoster (Shingrix) for prophylaxis. In JAN-2025, the patient received the 1st dose of Shingrix (unknown arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced injected limb mobility decreased (Verbatim: presented problems with her arm/ lifting her arm, locked to a certain point) and muscle tightness (Verbatim: Locked arm (tightness) after Shingrix first dose). The outcome of the injected limb mobility decreased was not reported and the outcome of the muscle tightness was unknown. It was unknown if the reporter considered the injected limb mobility decreased and muscle tightness to be related to Shingrix. It was unknown if the company considered the injected limb mobility decreased and muscle tightness to be related to Shingrix. Additional Information: GSK Receipt Date: 11-JUL-2025 A pharmacist wanted to know if Shingrix second dose could be administered anywhere else than the arm, given that with the first dose the patient presented problems with her arm, lifting her arm, locked to a certain point in 2025. No AE (adverse event) shared by the HCP (health care professional) other than patient's gender because that first dose was given in another facility of which he did not know the zip code.